SCOTT ROLKAGE CONTRIBUTION TO 5AM VENTURES

Scott Rocklage holds a prominent position as the managing partner at 5AM Ventures capital firm. This firm mainly deals with start-up investments, spinouts, early-stage, seed and growth capital. 5AM Ventures has a key focus towards making investments in medical technology, biotechnology, product discovery platforms and biopharmaceuticals. All those companies that show growth and strive to discover and develop drugs are given the highest priority by the capital firm. This is especially if these companies are more interested in therapeutic areas such as diabetes, metabolic diseases, anti-infectives and oncology (the scientific study of prevention, diagnosis, and treatment of cancer). Medical technology is an area of focus for 5AM ventures as it shows interest in materials science, imaging agents, diagnostics, drug delivery and medical devices.

Initially, Dr. Scott was just a venture partner at the firm in 2003. His position was elevated to managing partner in 2004 attributing to his impressive expertise in healthcare management and related fields. In his position, the doctor has been successful to enter a number of multiple drug candidates into clinical trials and has also led to FDA approving the three U.S. New Drug Application (Teslascan, Cubicin and Omniscan)Having been the president and the chief executive officer of Nycomed Salutar has given him a lot of experience in this field. To add on to this, he has served as the chief executive officer and chairman of Cubist Pharmaceuticals as well as holding various positions at Salutar and Catalytica.

Dr. Scott chairs the boards of Epirus (NASDAQ: EPRS) and Pulmatrix (NASDAQ: PULM). At the moment he is also a Board chairman of Kinestral, Rennovia, and Cidara (NASDAQ: CDTX). In the past, Dr. Scott was a Chairman of Relypsa (NASDAQ: CDTX) and Novira (acquired by Johnson and Johnson). To add more to his resume, Dr. Rocklage has previously been the Executive Chairman of Miikana (acquired by EntreMed), Ilypsa (acquired by Amgen) and Semprus (acquired by Teleflex). When he comes to his education, this successful doctor earned his Ph.D. in chemistry from the Massachusetts Institute of Technology (MIT). Here, the doctor left after conducting research activities in the laboratory of Richard R. Schrock (Nobel Prize in Chemistry in 2005).

 

To learn more, visit http://5amventures.com/team/scott-m-rocklage-phd/.

1 thought on “SCOTT ROLKAGE CONTRIBUTION TO 5AM VENTURES”

  1. While making some progress in science, it should give the necessary leverage if there should be a manager in some areas. But for sure topqualityassignment review should have given the necessary guide and information that is needed. Although this has taken some steps in career, it is normal for professors in top institutions to have such power.

Leave a Reply

Your email address will not be published. Required fields are marked *